GW
CYTK icon

GW & Wade’s Cytokinetics CYTK Stock Holding History

GW & Wade’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-20,000
Closed -$290K – 223
2017
Q3 		$290K Hold
20,000
– – 0.04% 195
2017
Q2 		$242K Hold
20,000
– – 0.03% 204
2017
Q1 		$257K Hold
20,000
– – 0.03% 202
2016
Q4 		$243K Hold
20,000
– – 0.04% 198
2016
Q3 		$184K Hold
20,000
– – 0.03% 218
2016
Q2 		$190K Hold
20,000
– – 0.03% 223
2016
Q1 		$141K Hold
20,000
– – 0.03% 205
2015
Q4 		$209K Hold
20,000
– – 0.04% 195
2015
Q3 		$134K Hold
20,000
– – 0.03% 212
2015
Q2 		$134K Buy
20,000
+10,000
+100% +$65.6K 0.03% 224
2015
Q1 		$68K Buy
+10,000
New +$74.7K 0.01% 237

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

GW & Wade's CYTK Position: Q4 2017 in Review

GW & Wade sold out of Cytokinetics (CYTK) in Q4 2017, closing a stake of 20,000 shares — an estimated $290K sold.

GW & Wade first reported a position in CYTK in Q1 2015 and held it in 11 quarters. The position peaked at $290K in Q3 2017. 134 funds tracked by Wall St. Rank hold CYTK as of Q4 2017.

  • GW & Wade reported no remaining Cytokinetics position as of Q4 2017 after selling out during the quarter.
  • GW & Wade sold 20,000 Cytokinetics shares in Q4 2017, an estimated $290K.
  • GW & Wade first reported a position in Cytokinetics in Q1 2015 and held it in 11 quarters.
  • GW & Wade's Cytokinetics position peaked at $290K in Q3 2017.
  • 134 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2017.

Based on GW & Wade's 13F filing for Q4 2017, filed 13 Feb 2018.